FDA Approved: ZEPBOUND — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approves a supplemental application for ZEPBOUND (tirzepatide) from Eli Lilly to update the drug's labeling related to weight management indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• ZEPBOUND (tirzepatide)

Snippet

SUPPL AP for ZEPBOUND (TIRZEPATIDE)